tirzepatide and visceral fat How Does Support Weight Management? Effect of tirzepatide on body
Description
Never discontinue semaglutide abruptly without medical guidance, as this may affect your diabetes control or weight management progress
The most common adverse events are gastrointestinal: nausea (44% of patients in Wegovy trials), diarrhoea (30%), vomiting (24%), and constipation (24%)
Clinical studies have demonstrated weight loss of 15 to 20 percent with lifestyle changes, underscoring semaglutide's effectiveness
Tirzepatide's injectable form bypasses the gastrointestinal tract entirely, avoiding complications from intestinal inflammation
